Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Cizzle Biotechnology Holdings PLC ( (GB:CIZ) ) has provided an update.
Cizzle Biotechnology has extended its strategic partnership with Cizzle Bio Inc to include the Caribbean, enhancing market reach for its CIZ1B biomarker lung cancer test. This expansion, accompanied by early royalty payments and a new laboratory contract, accelerates Cizzle’s market entry and strengthens its position in early cancer detection, promising significant commercial opportunities and improved cash flow.
More about Cizzle Biotechnology Holdings PLC
Cizzle Biotechnology Holdings PLC is a UK-based diagnostics developer focusing on early detection of lung cancer. The company is pioneering a blood test using the CIZ1B biomarker, a variant of a naturally occurring protein associated with early-stage cancer. Cizzle aims to commercialize its non-invasive, cost-effective test through strategic partnerships and licensing agreements.
YTD Price Performance: -7.69%
Average Trading Volume: 621,646
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £7.14M
See more insights into CIZ stock on TipRanks’ Stock Analysis page.
